Pepgen announces first patient dosed in connect1-edo51 phase 2 clinical trial of pgn-edo51 for duchenne muscular dystrophy patients amenable to exon 51 skipping

- preliminary data from the 5 mg/kg pgn-edo51 dose level in the connect1-edo51 phase 2 trial are expected mid-2024: including initial safety, exon 51 skipping and dystrophin protein production data -

PEPG Ratings Summary

PEPG Quant Ranking